Transgene (LTS:0OCQ) Short-Term Debt & Capital Lease Obligation : €0.02 Mil (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Transgene Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Transgene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.02 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Transgene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil.

Transgene Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Transgene's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Short-Term Debt & Capital Lease Obligation Chart

Transgene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

1.43

1.40

1.19

1.24

0.02

Transgene Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1.19	1.75	1.24	0.09	0.02

Transgene Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Transgene Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Transgene's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TRGNF:USA TNG:France TGNA:Germany

Address

400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Transgene Headlines

No Headlines